Indaptus Therapeutics reassesses decoy platform amid management shakeup and cash crunch

Indaptus Therapeutics (NASDAQ:INDP) announced a sweeping re-evaluation of its core developmental pipeline and resource allocation alongside a significant leadership transition, signaling a strategic pivot as the company faces tightening liquidity constraints.

The New York-based biotechnology firm disclosed that its board and incoming leadership are actively reassessing its proprietary Decoy immunotherapy platform.

The platform, which utilizes non-pathogenic bacteria to trigger innate and adaptive immune responses against solid tumors and viral infections, is being reviewed to establish stricter development priorities and maximize capital efficiency.

The structural pivot coincides with a sharp contraction in the firm's balance sheet.

Indaptus concluded the first quarter of 2026 with $1.5 million in cash and cash equivalents, representing a severe decline from the $8.5 million held at the close of fiscal year 2025.

The company attributed the reduction to $7 million in net cash used in operating activities during the three-month period, compounded by the fact that the company executed no capital-raising financing activities during the quarter.

To streamline its corporate overhead during this evaluation phase, all outstanding preferred shares were converted into common stock, removing potential dividend friction from its equity structure.

For the three months ended March 31, 2026, Indaptus reported a net loss of $2.5 million, or ($0.23) per share, narrowing from losses in previous quarters as a result of aggressive cost-containment measures.

Reflecting the pipeline slowdown, research and development (R&D) expenses fell to $0.5 million, while selling, general, and administrative (G&A) overhead dropped to $1.7 million.

Faced with a short cash runway, management stated that Indaptus is urgently seeking additional capital injection channels.

The company is actively evaluating an array of public and private financing mechanisms, alongside potential broader strategic options including partnerships, asset divestitures, or corporate combinations to sustain operations and advance its clinical targets